KR910000797A - 자기 단백질 접합체, 이의 제조방법 및 용도 - Google Patents

자기 단백질 접합체, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR910000797A
KR910000797A KR1019900008921A KR900008921A KR910000797A KR 910000797 A KR910000797 A KR 910000797A KR 1019900008921 A KR1019900008921 A KR 1019900008921A KR 900008921 A KR900008921 A KR 900008921A KR 910000797 A KR910000797 A KR 910000797A
Authority
KR
South Korea
Prior art keywords
conjugate
autoprotein
protein
antigen
cells
Prior art date
Application number
KR1019900008921A
Other languages
English (en)
Other versions
KR0154120B1 (ko
Inventor
헤르멘틴 페테르
되게스 라이너
프란센 우도
엔쓸레 카를하인쯔
프리센 하인쯔-외르겐
Original Assignee
스타인. 부크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인. 부크, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인. 부크
Publication of KR910000797A publication Critical patent/KR910000797A/ko
Application granted granted Critical
Publication of KR0154120B1 publication Critical patent/KR0154120B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

내용 없음

Description

자기 단백질 접합체, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 일반식(Ⅰ)의 자기단백질 접합체.
    M-NH-CO-(CH2)n-S-P (Ⅰ)
    상기식에서, n은 1내지 6, 바람직하게는 1또는 2, 특히 바람직하게는 1이고, M은 아미노 그룹을 지니는 분산성. 자기반응성 물질 또는 입자이고, P는 단백질이다.
  2. 제1항에 있어서, 단백질 P의 설프하이드릴 그룹 하나 또는 그 이상이 천연의 상태로 존재하거나, 디설파이드 결합의 환원에 의해 생성된 것이나, 화학반응에 의해 단백질에 도입된 자기단백질 접합체.
  3. 제1항에 있어서, P가 폴리클로날 면역 글로불린인 자기단백질 접합체.
  4. 제1항에 있어서, P가 모노클로날 항체 또는 Fab, Fab' 또는 F(ab')2단편인 자기단백질 접합체.
  5. 제1항에 있어서, P가 항원 또는 효소, 호르몬 렉틴 또는 성장인자의 잔기인 자기단백질 접합체.
  6. 제4항에 있어서, P가 IgG또는 IgM 부류의 모노클로날 항체인 자기단백질 접합체.
  7. 제4항에 있어서, P가 수성 염용액 또는 체액중에 용해된 상태로 존재하는 항원에 대해 직접적인 모노클로날 항체인 자기단백질 접합체.
  8. 제4항에 있어서, P가 세포상 특히, 척수 또는 림프계 세포 또는 말초혈액 특히, B림프구, T림프구 또는 이들의 전구세포의 세포상, 또는 종약세포 특히, 골수의 종양세포상에 발현된 항원에 대해 직접적인 모노클로날 항체인 자기단백질 접합체.
  9. 제4항에 있어서, P가 박테리아, 마이코플라즈마 또는 원생동물 또는 그외의 바이러스 상에서 발현된 항원에 대해 직접적인 모노클로날 항체인 자기단백질 접합체.
  10. 제1항에 있어서, P가 항원인 자기단백질 접합체.
  11. 제1항에 있어서, M은 메틸옥사이드 코어 및 아미노 그룹을 지니는 외피막을 지니는 분산성 입자이며, 이때, 상자성 물질의 그룹이 메탈옥사이드 코어에 박힐 수 있는 단백질 접합체.
  12. 제1항에 있어서, 입자의 직경이 약 0.1μ 내지 약 100μ, 바람직하게는 약 0.1μ 내지 약 1.5μ인 자기단백질 접합체.
  13. 아미노 그룹을 지닌 자기입자 M을 아미노 그룹과 반응하는 일반식(Ⅱ)의 할로 게노아실스케이서(spacer)와 반응시켜 아미드 결합을 생성시킴으로써 일반식(Ⅲ)화합물을 수득하고; 일반식(Ⅲ)화합물을 설프하이드릴 그룹을 지닌 단백질 P와 반응시켜 일반식(Ⅰ)의 화합물을 수득한후; 비공유적으로 결합된 단백질을 세척하여 제거시킴을 특징으로 하여, 일반식(Ⅰ)의 자기단백질 접합체를 제조하는 방법.
    상기식에서, n은 상기에서 정의한 바와 같고, X는 염소, 브롬 또는 요오드 원자이다.
  14. M 및 n이 제1항에서 정의한 바와 같고, X가 염소, 브롬 또는 요오드 원자인 일반식(Ⅲ) 화합물.
  15. 수성 염용액 또는 체액을 일반식(Ⅰ)의 적절한 자기단백질 접합체와 함께 배양하고, 제거하고자 하는 성분을 특이적으로 흡착시킨후, 자기단백질 접합체를 자기를 이용하여 분리하고, 필요할 경우, 특이적으로 흡착된 성분을 자기단백질 접합체로부터 재용출시킴을 특징으로 하여, 수성 염용액 또는 체액으로부터 용해된 상태의 항원, 항체, 수용체, 기질, 보조인자 또는 탄수화물 결정인자를 제거하는 방법.
  16. 세포 현탁액을 일반식(Ⅰ)의 적절한 자기단백질 접합체와 함께 배양하고, 제거하고자 하는 세포를 특이적으로 흡착시킨, 후 자기를 이용하여 자기단백질 집합체를 분리하고, 필요할 경우, 특이적으로 흡착된 세포 또는 입자를 자기단백질 접합체로부터 다시 분리시킴을 특징으로 하여, 수성 염용액 또는 체액으로부터 세포를 제거하는 방법.
  17. 수성 염용액 도는 체액으로부터 세포, 가용성 항원, 수용액, 기질, 보조인자 또는 탄수화물 결정인자를 특이적으로 제거하는데 사용하거나 진단방법의 일부 또는 진단제로서 사용하기 위한, 제1항의 자기단백질 접합체의 용도.
  18. 제8항 또는 9항의 세포제거, 바람직하게 골수고갈 또는 HLA 타이핑에 사용하기 위한, 제1항의 자기단백질 접합체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900008921A 1989-06-19 1990-06-18 자기단백질접합체 KR0154120B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3919873A DE3919873A1 (de) 1989-06-19 1989-06-19 Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
DE39198731 1989-06-19

Publications (2)

Publication Number Publication Date
KR910000797A true KR910000797A (ko) 1991-01-30
KR0154120B1 KR0154120B1 (ko) 1998-10-15

Family

ID=6382977

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900008921A KR0154120B1 (ko) 1989-06-19 1990-06-18 자기단백질접합체

Country Status (12)

Country Link
US (1) US5095097A (ko)
EP (1) EP0403961B1 (ko)
JP (1) JP2858883B2 (ko)
KR (1) KR0154120B1 (ko)
AT (1) ATE102052T1 (ko)
AU (1) AU639867B2 (ko)
CA (1) CA2019218C (ko)
DE (2) DE3919873A1 (ko)
DK (1) DK0403961T3 (ko)
ES (1) ES2063200T3 (ko)
IE (1) IE63666B1 (ko)
PT (1) PT94398B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2593192A (en) 1992-09-14 1994-04-12 Oystein Fodstad Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5585278A (en) * 1994-10-27 1996-12-17 Bayer Corporation Method for coupling antibody to novel latex substrate and its use in immunoassay
WO1997014443A1 (en) * 1995-10-19 1997-04-24 Bracco International B.V. Magnetically labeled chemoattractants as targeted contrast agents in the nmr imaging of living tissues
NO961031D0 (no) 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
DE69731982T2 (de) * 1996-03-26 2005-12-22 Cylex, Inc. Verfahren zur messung der lymphozytenfunktion
JP3662347B2 (ja) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 医療用粉体
US6379975B1 (en) * 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US7169571B2 (en) 1997-09-12 2007-01-30 Cylex, Inc. Methods for measurement of lymphocyte function
US6682940B2 (en) * 1999-05-04 2004-01-27 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
US6828157B1 (en) 1999-05-04 2004-12-07 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
CA2370215C (en) * 1999-05-04 2006-01-31 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
CN1488073A (zh) * 2001-04-17 2004-04-07 西莱克斯公司 利用促细胞分裂原和抗原测定淋巴细胞活化的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2334106A1 (fr) * 1975-12-02 1977-07-01 Pasteur Institut Gel magnetique convenant pour dosages immunoenzymatiques
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4698302A (en) * 1983-05-12 1987-10-06 Advanced Magnetics, Inc. Enzymatic reactions using magnetic particles
US4554088A (en) 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate

Also Published As

Publication number Publication date
EP0403961B1 (de) 1994-03-02
JP2858883B2 (ja) 1999-02-17
IE902194A1 (en) 1991-01-02
US5095097A (en) 1992-03-10
KR0154120B1 (ko) 1998-10-15
DK0403961T3 (da) 1994-06-27
IE902194L (en) 1990-12-19
IE63666B1 (en) 1995-05-31
EP0403961A2 (de) 1990-12-27
DE3919873A1 (de) 1990-12-20
JPH03184999A (ja) 1991-08-12
CA2019218C (en) 2001-01-02
ES2063200T3 (es) 1995-01-01
EP0403961A3 (de) 1991-07-17
PT94398A (pt) 1991-02-08
DE59004731D1 (de) 1994-04-07
AU5717890A (en) 1990-12-20
ATE102052T1 (de) 1994-03-15
CA2019218A1 (en) 1990-12-19
PT94398B (pt) 1997-01-31
AU639867B2 (en) 1993-08-05

Similar Documents

Publication Publication Date Title
KR910000797A (ko) 자기 단백질 접합체, 이의 제조방법 및 용도
Langone Applications of immobilized protein A in immunochemical techniques
US4550019A (en) Manufacture and use of fowl egg antibodies
CA1118344A (en) Bridging the sulphur atom of antigen, antibody or fragments to a substrate
CA1222449A (en) Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays
Fey et al. Methods of isolation, purification and quantitation of bovine immunoglobulins: a technical review
Dorval et al. Labeled Staphylococcai Protein A as an Immunological Probe in the Analysis of Cell Surface Markers
EP0525034B1 (en) Antigen/anti-antigen cleavage
JP6716683B2 (ja) 安定なナノ磁性粒子分散
KR880701378A (ko) 인간의 프로게스테론 수용체에 대한 항체와 진단용물질 및 진단법
JP2001520382A (ja) 安定なタンパク質−ニッケル粒子並びにその生産の方法及び使用
Strauss et al. Purification of human serum γ-globulin for immunologic studies: γ-globulin fragmentation after sulfate precipitation and prolonged dialysis
Bray et al. Use of a synthetic hapten in the demonstration of the Thomsen-Friedenreich (T) antigen on neuraminidase-treated human red blood cells and lymphocytes.
McIntosh et al. Evidence for an autologous immune complex pathogenic mechanism in acute poststreptococcal glomerulonephritis
CA1213828A (en) Purified and antigenically selective vaccines for domestic animals
US4687734A (en) Immunoassay for the detection of human colon cancer using a polyclonal antibody derived from a capillary culture of tumor cells
AU2013240942A1 (en) Method for producing reagent for antibody detection and use thereof
KR890014471A (ko) 자성 단백질 결합체, 이의 제조방법, 및 이의 용도
US5491218A (en) Artificial positive controls derived from bifunctional conjugates
WO1987002780A1 (en) Method of immunoassay
JPH05502098A (ja) 凝集検定
JPH0341098A (ja) 磁性蛋白質接合体およびその製造方法
JPH10505423A (ja) 細胞分離
Ahlstedt et al. Immunoradiometric assay for quantification of serum antibodies to dental plaque antigen in immunized dogs
Jewell et al. Quantitative radioimmunoassay of immunoglobulins on the surface of human tumor cells

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee